SYRE Stock Summary and Trading Ideas (Spyre Therapeutics | NASDAQ:SYRE)

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Spyre Therapeutics trades on the NASDAQ stock market under the symbol SYRE.

As of October 27, 2026, SYRE stock price climbed to $94.76 with 109,689 million shares trading.

SYRE has a beta of 1.88, meaning it tends to be more sensitive to market movements. SYRE has a correlation of 0.15 to the broad based SPY ETF.

SYRE has a market cap of $8.86 billion. This is considered a Mid Cap stock.

The top ETF exchange traded funds that SYRE belongs to (by Net Assets): VTI, IWM, VB, XBI, VBR.

SYRE has outperformed the market in the last year with a price return of +305.5% while the SPY ETF gained +14.4%. However, in the short term, SYRE had mixed performance relative to the market. It has underperformed in the last 3 months, returning -7.2% vs +4.1% return in SPY. But in the last 2 weeks, SYRE shares have fared better than the market returning +10.3% compared to SPY -1.4%.

SYRE support price is $89.02 and resistance is $96.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYRE shares will trade within this expected range on the day.